none20noPURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with clinical resistance to imatinib mesylate in chronic myeloid leukemia (CML) patients. To shed further light on the frequency, distribution, and prognostic significance of ABL mutations, we retrospectively analyzed a homogeneous cohort of late chronic phase CML patients who showed primary cytogenetic resistance to imatinib. PATIENTS AND METHODS: Using denaturing high-performance liquid chromatography (D-HPLC) and sequencing, we screened for ABL mutations in a total of 178 bone marrow and/or peripheral blood samples from 40 late chronic phase CML patients homogeneously treated with imatinib 400 mg/d, who did not reach a major cytogenetic...
Imatinib-treated chronic myeloid leukemia (CML) patients with acquired resistance commonly have dete...
BCR-ABL kinase domain mutations are infrequently detected in newly diagnosed chronic-phase chronic m...
AbstractThrough sequencing analysis of blood or bone marrow samples from patients with chronic myelo...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...
PURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
PURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Purpose: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Purpose: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Purpose: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Bcr-Abl kinase domain (KD) mutations may cause resistance to tyrosine kinase inhibitor (TKI) therapy...
Bcr-Abl kinase domain (KD) mutations may cause resistance to tyrosine kinase inhibitor (TKI) therapy...
Bcr-Abl kinase domain (KD) mutations may cause resistance to tyrosine kinase inhibitor (TKI) therapy...
<p>Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and s...
Imatinib-treated chronic myeloid leukemia (CML) patients with acquired resistance commonly have dete...
BCR-ABL kinase domain mutations are infrequently detected in newly diagnosed chronic-phase chronic m...
AbstractThrough sequencing analysis of blood or bone marrow samples from patients with chronic myelo...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...
Purpose Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with c...
PURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
PURPOSE: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Purpose: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Purpose: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Purpose: Point mutations within the ABL kinase domain of the BCR-ABL gene have been associated with ...
Bcr-Abl kinase domain (KD) mutations may cause resistance to tyrosine kinase inhibitor (TKI) therapy...
Bcr-Abl kinase domain (KD) mutations may cause resistance to tyrosine kinase inhibitor (TKI) therapy...
Bcr-Abl kinase domain (KD) mutations may cause resistance to tyrosine kinase inhibitor (TKI) therapy...
<p>Mutation status of 36 chronic myeloid leukemia (CML) patients in chronic phase with primary and s...
Imatinib-treated chronic myeloid leukemia (CML) patients with acquired resistance commonly have dete...
BCR-ABL kinase domain mutations are infrequently detected in newly diagnosed chronic-phase chronic m...
AbstractThrough sequencing analysis of blood or bone marrow samples from patients with chronic myelo...